These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 21050910)

  • 21. Evolution of β-blockers: from anti-anginal drugs to ligand-directed signalling.
    Baker JG; Hill SJ; Summers RJ
    Trends Pharmacol Sci; 2011 Apr; 32(4):227-34. PubMed ID: 21429598
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative analysis of beta-1 adrenoceptor agonist and antagonist potency and selectivity of cicloprolol, xamoterol and pindolol.
    Hicks PE; Cavero I; Manoury P; Lefevre-Borg F; Langer SZ
    J Pharmacol Exp Ther; 1987 Sep; 242(3):1025-34. PubMed ID: 2888869
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of a GPR23 cell-based β-lactamase reporter assay.
    Lee PH; Hanson BJ
    Methods Enzymol; 2010; 485():349-68. PubMed ID: 21050927
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Beta 3-receptors: incidence and properties, possible clinical significance].
    Gullestad L; Osnes JB
    Tidsskr Nor Laegeforen; 1995 Jan; 115(1):45-9. PubMed ID: 7846660
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Agonism and inverse agonism at dopamine D2-like receptors.
    Strange PG
    Clin Exp Pharmacol Physiol Suppl; 1999 Apr; 26():S3-9. PubMed ID: 10386247
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors.
    Seifert R; Wenzel-Seifert K
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Nov; 366(5):381-416. PubMed ID: 12382069
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic implications of beta-adrenergic receptor pharmacodynamic properties.
    Taira CA; Carranza A; Mayer M; Di Verniero C; Opezzo JA; Höcht C
    Curr Clin Pharmacol; 2008 Sep; 3(3):174-84. PubMed ID: 18781904
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The properties of beta-adrenoceptor antagonists.
    Shanks RG
    Postgrad Med J; 1976; 52 Suppl 4():14-20. PubMed ID: 9628
    [TBL] [Abstract][Full Text] [Related]  

  • 29. β(3)-Adrenoceptor agonists and (antagonists as) inverse agonists history, perspective, constitutive activity, and stereospecific binding.
    Grazia Perrone M; Scilimati A
    Methods Enzymol; 2010; 484():197-230. PubMed ID: 21036234
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human heart beta-adrenoceptors: beta1-adrenoceptor diversification through 'affinity states' and polymorphism.
    Molenaar P; Chen L; Semmler AB; Parsonage WA; Kaumann AJ
    Clin Exp Pharmacol Physiol; 2007 Oct; 34(10):1020-8. PubMed ID: 17714089
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Subtype-selective modulation of human beta 1- and beta 2-adrenoceptor function by beta-adrenoceptor agonists and antagonists.
    Brodde OE; Daul A; Michel MC
    Clin Physiol Biochem; 1990; 8 Suppl 2():11-7. PubMed ID: 1982757
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Beta blockers in migraine prophylaxis].
    Shimizu T
    Brain Nerve; 2009 Oct; 61(10):1125-30. PubMed ID: 19882938
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Physiological relevance of constitutive activity of 5-HT2A and 5-HT2C receptors.
    Berg KA; Harvey JA; Spampinato U; Clarke WP
    Trends Pharmacol Sci; 2005 Dec; 26(12):625-30. PubMed ID: 16269190
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Constitutive activity of histamine h(3) receptors stably expressed in SK-N-MC cells: display of agonism and inverse agonism by H(3) antagonists.
    Wieland K; Bongers G; Yamamoto Y; Hashimoto T; Yamatodani A; Menge WM; Timmerman H; Lovenberg TW; Leurs R
    J Pharmacol Exp Ther; 2001 Dec; 299(3):908-14. PubMed ID: 11714875
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Agonist and inverse agonist actions of beta-blockers at the human beta 2-adrenoceptor provide evidence for agonist-directed signaling.
    Baker JG; Hall IP; Hill SJ
    Mol Pharmacol; 2003 Dec; 64(6):1357-69. PubMed ID: 14645666
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intact cell binding properties of cells expressing altered beta-adrenergic receptors.
    Zhu SJ; Toews ML
    Mol Pharmacol; 1994 Feb; 45(2):255-61. PubMed ID: 7906855
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inverse agonists and antagonists of retinoid receptors.
    Bourguet W; de Lera AR; Gronemeyer H
    Methods Enzymol; 2010; 485():161-95. PubMed ID: 21050917
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Haemodynamic consequences of intrinsic sympathomimetic activity in relation to changes in plasma renin activity and noradrenaline during beta-blocker therapy for hypertension.
    Man in't Veld AJ; Schalekamp MA
    Postgrad Med J; 1983; 59 Suppl 3(689):140-58. PubMed ID: 6139800
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The beta-adrenergic system in man: physiological and pathophysiological response. Regulation of receptor density and functioning.
    Mäki T; Kontula K; Härkönen M
    Scand J Clin Lab Invest Suppl; 1990; 201():25-43. PubMed ID: 1978755
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of betahistine at histamine H3 receptors: mixed inverse agonism/agonism in vitro and partial inverse agonism in vivo.
    Gbahou F; Davenas E; Morisset S; Arrang JM
    J Pharmacol Exp Ther; 2010 Sep; 334(3):945-54. PubMed ID: 20530654
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.